semaj83/ctmatch_classification huggingface dataset:
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Myeloid Leukemia Allogeneic Haematopoietic Progenitor Cell Transplant Patient has decided voluntary to consent his or her participation signing the consent form before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care Patients with Acute myeloid Leukemia (AML), that will start induction chemotherapy or those patients submitted to an Allogeneic haematopoietic progenitor cell transplant The patient is >18 years old  Patient with prior Invasive Pulmonary Aspergillosis (IPA) history History of allergy or hypersensitivity to Amphotericin B Patient with intellectual deficit or patients with psychological alterations that make impossible the trial understanding Pregnancy or breastfeeding Patient has received other investigational drug or non traded product within 30 days before trial beginning Patient is enrolled in another clinical research study or/and is receiving an investigational agent for any reason Patient had major surgery within 4 weeks before enrollment
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 19.0-65.0,  Rheumatoid Arthritis Patients aged >35 and <=65 years with a diagnosis of rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) for at least 1 year and no more than 10 years prior to start of therapy; have active disease (Disease Activity Score [DAS] 28 >2.8 and <3.5), with changes in the DAS 28 score <0.6 within the 6 weeks before inclusion; have stable RA basic therapy according to standard for at least 3 months; have a chest X-ray within 1 month prior to first infusion with no evidence of malignancy, infections, or fibrosis; and have screening laboratory test results that meet prespecified criteria. Patient must have at least one swollen joint. Patient must have evidence of erosive disease by x-ray at baseline  Patients were excluded if they met any of the following Women who are pregnant, nursing, or planning pregnancy within 15 months after screening (i.e., approximately 6 months following last infusion) Use of any investigational drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer History of any other therapeutic agent targeted at reducing tumor necrosis factor (TNF) History of previous administration of infliximab History of receiving human/murine recombinant products or has a known allergy to murine products Serious infection (such as hepatitis, pneumonia or pyelonephritis) in the previous 3 months. Less serious infections (such as acute upper respiratory tract infection [colds] or simple urinary tract infection) need not be considered exclusions at the discretion of the investigator Active tuberculosis (TB) or evidence of latent TB (positive purified protein derivative [PPD] skin test, a history of old or latent TB or chest X-ray without adequate therapy for TB initiated prior to first infusion of study drug), or evidence of an old or latent TB infection without documented adequate therapy. Patients with a current close contact with an individual with active TB and patients who have completed treatment for active TB within the previous 2 years are explicitly excluded from the trial. Patients with a household member who has a history of active pulmonary TB should have had a thorough evaluation for TB prior to study enrollment as recommended by a local infectious disease specialist or published local guidelines of TB control agencies Hepatitis B surface antigen or Hepatitis C (HCV) antibody positive; documented Human Immunodeficiency Virus (HIV) infection Have an opportunistic infection, including but not limited to evidence of active cytomegalovirus, active pneumocystis carinii, aspergillosis, or atypical mycobacterium infection, etc, within the previous 6 months
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 6.0-999.0,  Cystic Fibrosis Diagnosis of CF as defined by two or more clinical features of CF and a documented sweat chloride greater than 60 mEq/L by quantitative pilocarpine iontophoresis test or a genotype showing two well characterized disease causing mutations Patient must be known to be chronically colonized with Aspergillus fumigatus Patients must be clinically stable at randomization, no use of new inhaled, oral or intravenous antibiotics or oral or intravenous corticosteroids during the 14-day period prior to randomization Patients must weigh at least 20 kg Post-menarche females must be using an effective form of contraception  Inability to give informed consent Respiratory culture positive for B.cepacia complex Renal function abnormalities-Creatinine greater than 1.5 times upper limit of normal within a 30 day period prior to randomization Liver function abnormalities : AST or ALT greater or equal to 2.5 times the upper limit of normal within a 30 day period prior to randomization Neutropenia, absolute neutrophil count&lt; or = 1000 within a 3-day period prior to randomization History of biliary cirrhosis documented by liver biopsy or imaging History of portal hypertension Investigational drug use within 30 days of randomization date History of alcohol, illicit drug or medication abuse within 1 year of randomization Women who are pregnant, breastfeeding or trying to conceive
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Arthritis, Rheumatoid Patients received placebo in main double-blind study (P04280, NCT00202852) Patients received Infliximab-containing regimen showing clinical response at week 30 in main double-blind study (P04280) [Main double-blind study (P04280, NCT00202852) criteria] Diagnosis of rheumatoid arthritis (RA) according to the revised 1987 of the American Rheumatism Association (Arnett et al, 1988). The disease should have been diagnosed >6 months prior to screening Active disease at the time of screening and pre-infusion as defined by >=6 swollen joints >=6 tender joints and of the following morning stiffness >=45 min erythrocyte sedimentation rate (ESR) >=28 mm/h  below of main double-blind study (P04280, NCT00202852) [Main double-blind study (P04280, NCT00202852) Pregnant women, nursing mothers, or a planned pregnancy within 1.5 years of enrollment Patients who are incapacitated, largely or wholly bedridden or confined to a wheelchair, and who have little or no ability for self-care Patients who have any current systemic inflammatory condition with signs and symptoms that might confound the evaluations of benefit from infliximab, eg Lyme disease, or a rheumatic disease other than RA Use of disease modifying anti-rheumatic drugs (DMARDs) other than MTX within 4 weeks prior to screening. (If a patient had prior exposure to leflunomide within the past 6 months, cholestyramine 8 g should be given 3 times daily for 11 days to rapidly lower the plasma level of leflunomide.) Use of intra-articular, i.m. or i.v. corticosteroids (including i.m. ACTH) within 4 weeks prior to screening Have been previously treated with infliximab or genetic recombinant therapy with RA (e.g. etanercept, adalimumab) Treatment with any other therapeutic agent targeted at reducing TNF (eg, pentoxifylline or thalidomide) within the previous 3 months Treatment with any investigational drug within the previous 3 months
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hidradenitis Suppurativa Subjects with moderate to severe HS as defined by a HSSI > 8 AND at least ONE of the following HS >1 year duration with multiple ER or doctors visits related to HS Intralesional kenalog injection >5/year, however none within 2 weeks of entry Failed systemic retinoids, but not within 3 months of entry Failed at least one prior course of antibiotic therapy, which must not have been administered within 2 weeks of entry to the study (excluding the recommended antibiotic regimen given for evidence of active infection immediately before enrollment) History of surgery (reconstructive), but not within 3 months of entry  Women who are pregnant, nursing, or planning pregnancy within 6 months after the last injection (this includes father's who plan on fathering a child within 6 months after their last injection) Use of other systemic anti-inflammatory medication except NSAIDs and low dose systemic steroids (equal or less than 10 mg daily prednisolone or equivalent) If found to have an active infection, patients must have completed topical or oral antibiotic therapy at least 7 days before first injection Have a known history of serious infections (e.g., hepatitis, pneumonia or pyelonephritis) in the previous 3 months Have or have had an opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening Have a history of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (e.g., nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic area), or splenomegaly Have a concomitant diagnosis or history of congestive heart failure Have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis, prior to screening
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Hematological Diseases Invasive Aspergillosis Age > 16 years Allogeneic HSCT for a haematological disease Written informed consent to the study  Pediatric patients
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer Diagnosis of non-small cell lung cancer Stage I-IIIB disease No prior surgical tumor resection Respiration-induced tumor motion > 5 mm Recruited by attending physician or research nurse at the Medical College of Virginia Hospitals Not pregnant No insufficient lung function or other parameters prohibiting a bronchoscopy Not a prisoner or institutionalized See Disease Characteristics Concurrent chemotherapy allowed
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 4.0-45.0,  Cystic Fibrosis, informed consent age between 4 and 45 years well-known Cystic fibrosis Lung function: FEV1 (% pred.) ≥ 70%  age < 4 and > 45 years lung function: FEV1 (% pred.)< 70% other chronic diseases or infections (e.g., HIV, tuberculosis, malignancy) pregnancy known alcohol, drug and/or drug abuse inability to capture the scale and scope of the study participation in another study
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 1.0-999.0,  Immunocompromised Host Invasive Pulmonary Fungal Infection Invasive Pulmonary Aspergillosis Invasive Pulmonary Zygomycosis Patients currently enrolled in any NIH IRB approved Clinical Center protocol or under treatment at the CNMC who are undergoing bronchoscopy or lung biopsy for diagnosis of possible invasive pulmonary aspergillosis or invasive pulmonary zygomycosis Informed consent of the patient or the patient's legally authorized representative Fulfillment of one or more of the following EORTC/MSG host History of neutropenia (ANC < 500/mm(3)) within the past 3 months temporally related to the onset of radiographic changes Receipt of an allogeneic HSCT Receipt of solid organ transplantation Prolonged use of corticosteroids at an average minimum dose of 0.3 mg/kg/day prednisone equivalent for > 3 weeks Treatment with other recognized T-cell immune suppressants such as cyclosporine, TNF alpha blockers, specific monoclonal antibodies such as alemtuzumab, nucleoside analogues during the past 90 days Myelodysplastic syndrome Severe aplastic anemia  Interstitial or diffuse infiltrates on chest CT or radiograph Inability to provide informed consent Children weighing less than 10 kg Any other concomitant condition, which in the opinion of the investigator would place the patient at risk by participating in the study
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Infection Pulmonary TB Age above 18 years HIV-1/2 infected patients with Pulmonary TB. This includes sputum smear positive disease Initially smear negative but (Becton-Dickinson) culture positive (e.g. miliary TB, Mediastinal adenitis and Chest x-ray with persistent abnormality after antibiotics) Persistent X-ray abnormality will be included for allocation. However final into both ITT and efficacy analysis will depend on positivity in LJ culture Living within 40 km radius from the nearest sub centre of TRC and willing for attendance as prescribed Likely to remain in the same area for at least one and half years after start of treatment Willing for house visits and surprise checks Willing to participate and give informed consent after going through the terms and conditions of the trial  Patients with known hypersensitivity to rifampicin Pregnancy and lactation at initial presentation Major complications like HIV encephalopathy, renal dysfunction (serum creatinine > 1.5 mg% in the absence of dehydration) or jaundice (serum bilirubin > 2 mgs% along with SGOT /SGPT elevation > 2.5 times the upper limit of normal) Previous anti-tuberculosis treatment for more than 1 month. Prophylaxis (non-rifampicin containing regimen) will not be considered as prior antituberculosis treatment Moribund, bedridden or unconscious patients Co-morbid conditions like uncontrolled diabetes mellitus, cardiac failure, and malignancy at initial presentation Major psychiatric illness Patients on second line ART, mainly protease inhibitors, at initial presentation
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Allergic Bronchopulmonary Aspergillosis Diagnosis of ABPA Presence of all the following three immediate cutaneous hyperreactivity on aspergillus skin test elevated total IgE levels > 1000 IU/mL A fumigatus specific IgE levels > 0.35 kU/L, AND Presence of two of the following presence of serum precipitating antibodies against A fumigatus fixed or transient radiographic pulmonary opacities absolute eosinophil count > 1000/µL central bronchiectasis on HRCT  If they have taken glucocorticoids for more than three weeks in the preceding six months Failure to give informed consent Enrollment in another trial of ABPA
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Liver Transplantation Aspergillus Interleukin-17 Treg Cell Immune Tolerance Liver transplantation patients  Psychopath
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Invasive Aspergillosis BAL in hematological neutropenic patients at high risk of IA, admitted to our hospital, in which we usually perform a BAL for microbiological study when they present persistent fever and an opportunist infection suspicion BAL in patients without hematological illness and without IA suspicion, in which we perform an BAL because of another reason  Patients without fulfilling criteria Patients with some contraindication to perform a bronchoscopy
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 35.0-85.0,  Osteoarthritis, Knee Adults ≥ age 35 but ≤ age 85 Painful knees for 3-60 months VAS joint pain score greater than 30 mm (scale 0-100) Knee radiograph showing minimal to moderate change (early OA) No NSAID therapy for at least one week Have the capacity to understand and sign an informed consent form Gender: Male or female Women must be postmenopausal (no menstrual period for a minimum of 1 year) or surgically sterilized and have a negative serum pregnancy test on entry in the study. Men must agree to use adequate birth control during the study for 6 months after the infusion of study agent Men and women of childbearing potential must use adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization) for the duration of the study and should continue such precautions for 6 months after receiving the last infusion The screening laboratory test results must meet the following  Moderate to Severe OA, as determined by severe joint space narrowing (Kellgren grade IV) (7) in medial and lateral compartments Insulin-dependent diabetes mellitus Systemic inflammatory illness, e.g. rheumatoid arthritis Intra-articular injections within 3 months Prior treatment with infliximab or other anti-TNF drug Acute injury to knees (< 2 weeks) Women who are pregnant, nursing, or planning pregnancy within 6 months after the last infusion (this includes father's who plan on fathering a child within 6 months after their last infusion) Have had any previous treatment with monoclonal antibodies or antibody fragments History of receiving human/murine recombinant products or a known allergy to murine products. A known allergy to murine product is definitely an criterion Documentation of a positive test for hepatitis B surface antigen or hepatitis C
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Invasive Aspergillosis proven or probable invasive aspergillosis with positive GM antigen test  Seronegative aspergillosis
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Hematologic Disease Solid Organ Transplantation IPA cases with solid organ transplant recipients and hematologic disease patients proven and probable invasive pulmonary aspergillosis by modified EORTC/MSG  under 16 years old possible cases of invasive pulmonary aspergillosis